eCTD Structure Explained: Complete Guide to Modules, Folders, and XML Backbone
The eCTD structure is the standardized organizational framework consisting of five modules (Administrative, Summaries, Quality, Nonclinical, Clinical), an XML backbone for navigation, and a defined folder hierarchy that regulatory agencies worldwide require. Only Module 1 varies by region (FDA, EMA, Health Canada); Modules 2-5 are harmonized globally. Structural errors cause gateway rejections, so mastering the eCTD structure is essential for regulatory submission success.
Key Takeaways
Key Takeaways
- The eCTD has five modules: Module 1 (regional administrative), Module 2 (summaries), Module 3 (quality/CMC), Module 4 (nonclinical), and Module 5 (clinical)
- Module 1 is the only region-specific module; Modules 2-5 follow harmonized ICH M4 structure accepted by FDA, EMA, Health Canada, and 60+ agencies
- The XML backbone (index.xml) provides the navigation structure linking all documents and must validate against the ICH DTD schema
- Total file path length must not exceed 180 characters, and all file/folder names must use lowercase with no spaces or special characters
- The eCTD structure is the standardized organizational framework for Electronic Common Technical Document (eCTD) submissions, consisting of five hierarchical modules, an XML backbone for navigation, and a defined folder hierarchy that regulatory agencies worldwide require for drug and biologic applications. The eCTD structure ensures consistent presentation of regulatory data across FDA, EMA, Health Canada, and 60+ other agencies.
- Understanding the eCTD structure is fundamental to successful regulatory submissions. A submission that follows perfect formatting but violates structural requirements will be rejected at the gateway. Conversely, mastering the eCTD structure enables faster assembly, easier amendments, and smoother regulatory review.
- In this guide, you'll learn:
- The complete breakdown of eCTD modules 1, 2, 3, 4, and 5 with their specific purposes
- How the XML backbone creates navigable submission structure
- The exact folder hierarchy and naming conventions required by ICH M8
- Regional structural differences between FDA, EMA, and other agencies
- How the CTD format evolved into the modern eCTD structure
- ---
What Is eCTD Structure?
The eCTD structure is the standardized organizational architecture that defines how pharmaceutical regulatory submissions are assembled, formatted, and presented to health authorities. It encompasses three interconnected layers: five-module content organization, an XML backbone that provides navigation, and a file system hierarchy containing all documents, with Modules 2-5 harmonized globally and Module 1 varying by regulatory authority.
The eCTD structure is the standardized organizational architecture that defines how pharmaceutical regulatory submissions are assembled, formatted, and presented to health authorities. This structure encompasses three interconnected layers: the five-module content organization, the XML backbone that provides navigation, and the file system hierarchy that contains all documents.
Key characteristics of eCTD structure:
- Five-module organization based on ICH M4 Common Technical Document
- XML backbone files (index.xml, regional.xml) providing navigable structure
- Standardized folder naming following ICH M8 specifications
- Leaf-level document organization within each module
- Lifecycle management through sequence numbering
- Harmonized content structure (Modules 2-5) with regional variation (Module 1)
The eCTD structure was first published as ICH M8 in 2003 and has been updated through multiple versions, with eCTD v3.2.2 being the most widely implemented and eCTD v4.0 introducing significant structural enhancements.
The eCTD structure serves two critical purposes: it provides regulatory reviewers with a predictable, navigable organization for efficient assessment, and it enables sponsors to manage complex submissions with thousands of documents across global markets.
The CTD Format: Foundation of eCTD Structure
The CTD format (Common Technical Document format) is the organizational blueprint that the eCTD structure implements electronically. Understanding the CTD format is essential because the eCTD directly mirrors its content organization.
History of the CTD Format
The CTD format emerged from the International Council for Harmonisation (ICH) effort to standardize regulatory submissions across regions:
| Year | Milestone | Impact on Structure |
|---|---|---|
| 1996 | ICH M4 working group formed | Began defining common structure |
| 2000 | CTD specification finalized | Established 5-module organization |
| 2003 | eCTD v1.0 published (ICH M8) | Electronic implementation defined |
| 2008 | eCTD v3.2 released | Refined structural requirements |
| 2016 | eCTD v4.0 specification | Introduced XML-based structure |
| 2024 | eCTD v4.0 regional adoption | FDA and other agencies implementing |
The CTD Triangle
The CTD triangle is a visual representation of how submission content flows from detailed data to summarized overviews:
This structure enables reviewers to start with summaries (Module 2) and drill down into supporting detail (Modules 3, 4, 5) as needed.
CTD Format vs eCTD Structure
| Aspect | CTD Format | eCTD Structure |
|---|---|---|
| Medium | Paper-based | Electronic (XML + PDF) |
| Navigation | Physical tabs and dividers | XML backbone hyperlinks |
| Module organization | Same 5-module structure | Same 5-module structure |
| File format | Paper or PDF binders | PDF with XML metadata |
| Updates | Complete section replacement | Granular leaf operations |
| Lifecycle tracking | Manual version control | Sequence-based tracking |
| Current usage | Legacy only | Global standard |
Complete eCTD Modules Breakdown
The eCTD structure organizes all submission content into five modules. Understanding each module's purpose and content is essential for proper eCTD structure implementation.
eCTD Module Overview Table
| Module | Name | Content Focus | Regional Status | Typical Size |
|---|---|---|---|---|
| Module 1 | Administrative Information | Forms, labeling, correspondence | Region-specific | 50-200 docs |
| Module 2 | Common Technical Document Summaries | Quality, nonclinical, clinical overviews | Harmonized | 30-50 docs |
| Module 3 | Quality | Drug substance and drug product CMC | Harmonized | 200-1000 docs |
| Module 4 | Nonclinical Study Reports | Pharmacology, PK, toxicology | Harmonized | 50-300 docs |
| Module 5 | Clinical Study Reports | All clinical studies and data | Harmonized | 500-5000+ docs |
Module 1: Administrative Information and Prescribing Information
Module 1 is the only region-specific module in the eCTD structure. Its organization differs between FDA, EMA, Health Canada, and other regulatory authorities.
Module 1 Purpose:
- Contains all administrative documents required by the specific regulatory authority
- Houses product labeling in the regional format
- Includes regulatory correspondence and forms
- Provides region-specific information not included in harmonized modules
FDA Module 1 Structure:
| Section | Content | Key Documents |
|---|---|---|
| 1.1 | Forms | FDA 356h, 1571, 3674 |
| 1.2 | Cover Letter | Submission cover letter |
| 1.3 | Administrative Information | Patent info, exclusivity, fees |
| 1.4 | References | Literature not in Module 5 |
| 1.5 | Application Status | Field copy certification |
| 1.6-1.10 | Regional Administrative | Financial disclosure, PDUFA |
| 1.11 | Pediatric Administrative | Pediatric assessments |
| 1.12 | Other | REMS, promotional materials |
| 1.14 | Labeling | USPI, patient labeling, labels |
| 1.15 | Promotional Materials | Advertising and promotional items |
| 1.16 | Risk Management | Risk mitigation materials |
EMA Module 1 Structure:
| Section | Content | Key Documents |
|---|---|---|
| 1.0 | Cover Letter | Application cover letter |
| 1.2 | Application Form | EMA forms |
| 1.3 | Product Information | SmPC, Annex II, Package Leaflet |
| 1.4 | Expert Statements | QP declarations |
| 1.5 | Specific Information | Special requirements |
| 1.6 | Environmental Risk | ERA documentation |
| 1.7 | Orphan Information | Orphan designation documents |
| 1.8 | Pharmacovigilance | PSMF, RMP reference |
| 1.9 | Clinical Trials | EudraCT references |
| 1.10 | Responses | Response to questions |
Always create your Module 1 structure based on your submission's specific regulatory path before authoring begins. FDA, EMA, and Health Canada require different section numbering and documents. Pre-planning your Module 1 structure prevents last-minute reorganization that delays submission and introduces errors.
Module 2: Common Technical Document Summaries
Module 2 provides the summaries and overviews that reviewers read first. This module synthesizes all data from Modules 3, 4, and 5 into accessible narrative form.
Module 2 Structure:
| Section | Title | Content | Cross-References To |
|---|---|---|---|
| 2.1 | CTD Table of Contents | Navigation index | Entire submission |
| 2.2 | CTD Introduction | Product overview | All modules |
| 2.3 | Quality Overall Summary (QOS) | CMC summary | Module 3 |
| 2.4 | Nonclinical Overview | Nonclinical interpretation | Module 4 |
| 2.5 | Clinical Overview | Clinical interpretation | Module 5 |
| 2.6 | Nonclinical Written and Tabulated Summaries | Detailed nonclinical summary | Module 4 |
| 2.7 | Clinical Summary | Detailed clinical summary | Module 5 |
Module 2.3 Quality Overall Summary Subsections:
| Subsection | Content |
|---|---|
| 2.3.S | Drug Substance summary |
| 2.3.S.1 | General information |
| 2.3.S.2 | Manufacture |
| 2.3.S.3 | Characterization |
| 2.3.S.4 | Control of drug substance |
| 2.3.S.5 | Reference standards |
| 2.3.S.6 | Container closure system |
| 2.3.S.7 | Stability |
| 2.3.P | Drug Product summary |
| 2.3.P.1 | Description and composition |
| 2.3.P.2 | Pharmaceutical development |
| 2.3.P.3 | Manufacture |
| 2.3.P.4 | Control of excipients |
| 2.3.P.5 | Control of drug product |
| 2.3.P.6 | Reference standards |
| 2.3.P.7 | Container closure system |
| 2.3.P.8 | Stability |
| 2.3.A | Appendices |
| 2.3.R | Regional information |
Module 3: Quality (Chemistry, Manufacturing, and Controls)
Module 3 contains the complete Chemistry, Manufacturing, and Controls (CMC) data for both drug substance and drug product. This module follows the ICH M4Q structure.
Module 3 Structure:
| Section | Title | Content Type |
|---|---|---|
| 3.2.S | Drug Substance | |
| 3.2.S.1 | General Information | Nomenclature, structure, properties |
| 3.2.S.2 | Manufacture | Process description, controls, validation |
| 3.2.S.3 | Characterization | Structure elucidation, impurities |
| 3.2.S.4 | Control of Drug Substance | Specifications, analytical methods, batch data |
| 3.2.S.5 | Reference Standards | Primary and secondary standards |
| 3.2.S.6 | Container Closure System | Packaging description and suitability |
| 3.2.S.7 | Stability | Stability protocol, data, and summary |
| 3.2.P | Drug Product | |
| 3.2.P.1 | Description and Composition | Dosage form, formulation |
| 3.2.P.2 | Pharmaceutical Development | Formulation, process development |
| 3.2.P.3 | Manufacture | Process, controls, validation |
| 3.2.P.4 | Control of Excipients | Excipient specifications |
| 3.2.P.5 | Control of Drug Product | Specifications, methods, batch data |
| 3.2.P.6 | Reference Standards | Product-related standards |
| 3.2.P.7 | Container Closure System | Primary and secondary packaging |
| 3.2.P.8 | Stability | Stability data and commitments |
| 3.2.A | Appendices | Supporting data |
| 3.2.A.1 | Facilities and Equipment | Site information |
| 3.2.A.2 | Adventitious Agents Safety | Biological safety data |
| 3.2.A.3 | Excipients | Novel excipient information |
| 3.2.R | Regional Information | Region-specific CMC data |
Module 4: Nonclinical Study Reports
Module 4 contains all nonclinical (animal and in vitro) studies following the ICH M4S structure. This module organizes pharmacology, pharmacokinetics, and toxicology data.
Module 4 Structure:
| Section | Title | Study Types Included |
|---|---|---|
| 4.2.1 | Pharmacology | |
| 4.2.1.1 | Primary Pharmacodynamics | Mechanism of action studies |
| 4.2.1.2 | Secondary Pharmacodynamics | Off-target effect studies |
| 4.2.1.3 | Safety Pharmacology | CV, CNS, respiratory safety |
| 4.2.1.4 | Pharmacodynamic Drug Interactions | PD DDI studies |
| 4.2.2 | Pharmacokinetics | |
| 4.2.2.1 | Analytical Methods | Bioanalytical validation |
| 4.2.2.2 | Absorption | Absorption studies |
| 4.2.2.3 | Distribution | Tissue distribution, protein binding |
| 4.2.2.4 | Metabolism | In vitro and in vivo metabolism |
| 4.2.2.5 | Excretion | Mass balance, excretion routes |
| 4.2.2.6 | Pharmacokinetic Drug Interactions | PK DDI studies |
| 4.2.2.7 | Other Pharmacokinetic Studies | Additional PK data |
| 4.2.3 | Toxicology | |
| 4.2.3.1 | Single-Dose Toxicity | Acute toxicity studies |
| 4.2.3.2 | Repeat-Dose Toxicity | Subacute, subchronic, chronic |
| 4.2.3.3 | Genotoxicity | In vitro and in vivo genotox |
| 4.2.3.4 | Carcinogenicity | Long-term carcinogenicity |
| 4.2.3.5 | Reproductive Toxicity | Fertility, EFD, PPND studies |
| 4.2.3.6 | Local Tolerance | Injection site, dermal studies |
| 4.2.3.7 | Other Toxicity Studies | Immunotox, phototox, mechanistic |
Module 5: Clinical Study Reports
Module 5 is typically the largest module, containing all clinical study reports and supporting clinical data following ICH E3 format requirements.
Module 5 Structure:
| Section | Title | Content Type |
|---|---|---|
| 5.2 | Tabular Listing of Clinical Studies | Index of all studies |
| 5.3.1 | Biopharmaceutic Studies | |
| 5.3.1.1 | Bioavailability Studies | BA study reports |
| 5.3.1.2 | Comparative BA and BE Studies | BE study reports |
| 5.3.1.3 | In Vitro-In Vivo Correlation | IVIVC studies |
| 5.3.1.4 | Bioanalytical Methods | Clinical bioanalysis validation |
| 5.3.2 | PK Using Human Biomaterials | |
| 5.3.2.1 | Plasma Protein Binding | Protein binding studies |
| 5.3.2.2 | Hepatic Metabolism | In vitro metabolism |
| 5.3.2.3 | Drug Interactions | In vitro DDI studies |
| 5.3.3 | PK and Initial Tolerability | |
| 5.3.3.1 | Healthy Subject PK | Phase 1 PK studies |
| 5.3.3.2 | Patient PK | Patient population PK |
| 5.3.3.3 | Intrinsic Factors | Renal/hepatic impairment |
| 5.3.3.4 | Extrinsic Factors | DDI clinical studies |
| 5.3.3.5 | Population PK | PopPK analyses |
| 5.3.4 | Pharmacodynamics | |
| 5.3.4.1 | Healthy Subject PD | PD studies in healthy volunteers |
| 5.3.4.2 | Patient PD and PK/PD | PK/PD modeling, patient PD |
| 5.3.5 | Efficacy and Safety | |
| 5.3.5.1 | Efficacy/Safety - Controlled Studies | Pivotal efficacy trials |
| 5.3.5.2 | Efficacy/Safety - Uncontrolled Studies | Supportive studies |
| 5.3.5.3 | Analyses Across Studies | ISS, ISE, pooled analyses |
| 5.3.5.4 | Other Efficacy/Safety Studies | Registry, observational |
| 5.3.6 | Post-Marketing | |
| 5.3.6 | Post-Marketing Reports | Post-market safety data |
| 5.3.7 | CRFs and Individual Patient Data | |
| 5.3.7 | Case Report Forms | CRFs and listings |
| 5.4 | Literature References | Published literature |
eCTD Folder Hierarchy and File Organization
The eCTD structure defines exact folder naming conventions and file organization that must be followed precisely. This folder hierarchy enables automated validation and consistent navigation.
Root Level Folder Structure
The eCTD uses sequence folders at the root level to track submission lifecycle:
Module Folder Naming Conventions
Each module follows specific folder naming rules defined by ICH M8:
Module 1 Folder Structure (FDA Example):
Module 2 Folder Structure:
Module 3 Folder Structure:
File Naming Requirements
The eCTD structure enforces strict file naming conventions:
| Rule | Requirement | Example |
|---|---|---|
| Character limit | Maximum 64 characters including extension | clinical-study-report.pdf |
| Allowed characters | Lowercase a-z, digits 0-9, hyphen | study-001-csr.pdf |
| Prohibited characters | Spaces, uppercase, special characters | NOT Study 001 CSR.pdf |
| Extension case | Lowercase only | .pdf not .PDF |
| Path limit | Total path should not exceed 180 characters | - |
File Naming Comparison:
| Compliant | Non-Compliant | Reason |
|---|---|---|
efficacy-study-001.pdf | Efficacy Study 001.pdf | Uppercase and spaces |
module-2-3-qos.pdf | module 2.3 QOS (final).pdf | Spaces and parentheses |
batch-analysis-12345.pdf | batch_analysis_12345.PDF | Underscore and uppercase extension |
csr-pk-phase1.pdf | CSR PK Phase I (v2.0).pdf | Multiple violations |
Implement file naming conventions early in your document authoring process. Create a naming standard document and share it with all contributors (writers, scientists, regulatory). This prevents expensive late-stage file renaming and ensures consistency across thousands of submission documents.
eCTD XML Backbone Structure
The XML backbone is the navigation layer of the eCTD structure. It creates the hyperlinked table of contents that enables reviewers to navigate through thousands of documents.
XML Backbone Components
| XML File | Purpose | Contains |
|---|---|---|
index.xml | Master navigation | Links to all modules and regional XML |
us-regional.xml | FDA-specific metadata | US Module 1 information |
eu-regional.xml | EMA-specific metadata | EU Module 1 information |
ca-regional.xml | Health Canada metadata | Canadian Module 1 information |
Index.xml Structure
The index.xml file serves as the entry point for the entire submission: